The FDA approved a new long-acting drug for schizophrenia and bipolar disorder on Thursday, adding to the growing rank of drugs for the mental disorders that don’t have to be taken as an oral daily treatment. Otsuka and Lundbeck's Abilify Asimtufii (aripipraz…